Cailin T Collins1, Jay L Hess. 1. aDepartment of Pathology, University of Michigan, Ann Arbor, MichiganbIndiana University School of Medicine, Indianapolis, Indiana, USA.
Abstract
PURPOSE OF REVIEW: HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. RECENT FINDINGS: A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. SUMMARY: HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.
PURPOSE OF REVIEW: HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. RECENT FINDINGS: A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. SUMMARY:HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.
Authors: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Marta Pratcorona; Saman Abbas; Jenny E Kuipers; Janneke F van Galen; H Berna Beverloo; Edwin Sonneveld; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Martin Zimmermann; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; Peter J M Valk; C Michel Zwaan Journal: Blood Date: 2011-08-02 Impact factor: 22.113
Authors: Sara C Monroe; Stephanie Y Jo; Daniel S Sanders; Venkatesha Basrur; Kojo S Elenitoba-Johnson; Robert K Slany; Jay L Hess Journal: Exp Hematol Date: 2010-09-18 Impact factor: 3.084
Authors: Nadine Martin; Nikolay Popov; Francesca Aguilo; Ana O'Loghlen; Selina Raguz; Ambrosius P Snijders; Gopuraja Dharmalingam; Side Li; Efstathia Thymiakou; Thomas Carroll; Bernd B Zeisig; Chi Wai Eric So; Gordon Peters; Vasso Episkopou; Martin J Walsh; Jesús Gil Journal: EMBO J Date: 2013-03-01 Impact factor: 11.598
Authors: Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan Journal: Genes Chromosomes Cancer Date: 2017-03-31 Impact factor: 5.006
Authors: Narasimhan P Agaram; Lei Zhang; Yun-Shao Sung; Marcela S Cavalcanti; Dianne Torrence; Leonard Wexler; Glenn Francis; Scott Sommerville; David Swanson; Brendan C Dickson; Albert J H Suurmeijer; Richard Williamson; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2019-05 Impact factor: 6.394
Authors: Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman Journal: Blood Date: 2018-05-03 Impact factor: 22.113
Authors: Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess Journal: Cancer Cell Date: 2018-09-27 Impact factor: 31.743
Authors: Liat Goldberg; Vijay Negi; Yang Jo Chung; Masahiro Onozawa; Yuelin J Zhu; Robert L Walker; Rachel Pierce; Daxesh P Patel; Kristopher W Krausz; Frank J Gonzalez; Margaret A Goodell; Benjamin A T Rodriguez; Paul S Meltzer; Peter D Aplan Journal: Cancer Res Date: 2021-07-28 Impact factor: 13.312